Apexicon E
Loading...Apexicon E Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
History
There is currently no drug history available for this drug.
Other Information
Each gram of ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) contains 0.5 mg diflorasone diacetate in a cream base for topical dermatological use.
Chemically, diflorasone diacetate is: 6α,9-difluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate.
The structural formula is represented below:
Each gram of ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) contains: 0.5 mg diflorasone diacetate in a hydrophilic vanishing cream base of propylene glycol, stearyl alcohol, cetyl alcohol, sorbitan monostearate, polysorbate 60, mineral oil and purified water.
Sources
Apexicon E Manufacturers
-
Pharmaderm, A Division Of Nycomed Us Inc.
![Apexicon E (Diflorasone Diacetate) Cream [ Pharmaderm, A Division Of Nycomed Us Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Apexicon E | Pharmaderm, A Division Of Nycomed Us Inc.
ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) should be applied to the affected areas as a thin film from one to three times daily depending on the severity or resistant nature of the condition.
Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.
-
Pharmaderm A Division Of Fougera Pharmaceuticals Inc.
Apexicon E | Pharmaderm A Division Of Fougera Pharmaceuticals Inc.
ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) should be applied to the affected areas as a thin film from one to three times daily depending on the severity or resistant nature of the condition.
Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.
![Apexicon E (Diflorasone Diacetate) Cream [Pharmaderm A Division Of Fougera Pharmaceuticals Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=af4c413b-c228-48f0-9ad0-6434d1f921b9&name=apexicon-e-cream-02.jpg)
Login To Your Free Account